LL-37 (Cathelicidin) Dosage Guide

Complete guide to LL-37 (Cathelicidin) dosing protocols, administration methods, and safety considerations for research purposes.

Research Use Only: The dosage information provided is for educational and research purposes. Peptides are not approved by the FDA for human use. Always consult with a healthcare professional.

Recommended Dosage

Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections.

Administration Method

Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols.

Side Effects to Monitor

Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses.

Safety Considerations & Risks

May overstimulate immune system in autoimmune conditions. Limited human research data. Quality and purity concerns with research products.